Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer

Makoto Shinoto, Shigeru Yamada, Shigeo Yasuda, Hiroshi Imada, Yoshiyuki Shioyama, Hiroshi Honda, Tadashi Kamada, Hirohiko Tsujii, Hiromitsu Saisho

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Background: The authors evaluated the tolerance and efficacy of carbon-ion radiotherapy (CIRT) as a short-course, preoperative treatment and determined the recommended dose needed to reduce the risk of postoperative local recurrence without excess injury to normal tissue. Methods: Patients radiographically defined with potentially resectable pancreatic cancer were eligible. A preoperative, short-course, dose-escalation study was performed with fixed 8 fractions in 2 weeks. The dose of irradiation was increased by 5% increments from 30 grays equivalents (GyE) to 36.8 GyE. Surgery was to be performed 2 to 4 weeks after the completion of CIRT. Results: The study enrolled 26 patients. At the time of restaging after CIRT, disease progression with distant metastasis or refusal ruled out 5 patients from surgery. Twenty-one of 26 patients (81%) patients underwent surgery. The pattern of initial disease progression was distant metastasis in 17 patients (65%) and regional recurrence in 2 patients (8%). No patients experienced local recurrence. The 5-year survival rates for all 26 patients and for those who underwent surgery were 42% and 52%, respectively. Conclusions: Preoperative, short-course CIRT followed by surgery is feasible and tolerable without unacceptable morbidity.

Original languageEnglish
Pages (from-to)45-51
Number of pages7
JournalCancer
Volume119
Issue number1
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

Heavy Ion Radiotherapy
Pancreatic Neoplasms
Recurrence
Disease Progression
Neoplasm Metastasis
Survival Rate

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. / Shinoto, Makoto; Yamada, Shigeru; Yasuda, Shigeo; Imada, Hiroshi; Shioyama, Yoshiyuki; Honda, Hiroshi; Kamada, Tadashi; Tsujii, Hirohiko; Saisho, Hiromitsu.

In: Cancer, Vol. 119, No. 1, 01.01.2013, p. 45-51.

Research output: Contribution to journalArticle

Shinoto, M, Yamada, S, Yasuda, S, Imada, H, Shioyama, Y, Honda, H, Kamada, T, Tsujii, H & Saisho, H 2013, 'Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer', Cancer, vol. 119, no. 1, pp. 45-51. https://doi.org/10.1002/cncr.27723
Shinoto, Makoto ; Yamada, Shigeru ; Yasuda, Shigeo ; Imada, Hiroshi ; Shioyama, Yoshiyuki ; Honda, Hiroshi ; Kamada, Tadashi ; Tsujii, Hirohiko ; Saisho, Hiromitsu. / Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer. In: Cancer. 2013 ; Vol. 119, No. 1. pp. 45-51.
@article{55c7efabcf11478b84484f2b5aebf68e,
title = "Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer",
abstract = "Background: The authors evaluated the tolerance and efficacy of carbon-ion radiotherapy (CIRT) as a short-course, preoperative treatment and determined the recommended dose needed to reduce the risk of postoperative local recurrence without excess injury to normal tissue. Methods: Patients radiographically defined with potentially resectable pancreatic cancer were eligible. A preoperative, short-course, dose-escalation study was performed with fixed 8 fractions in 2 weeks. The dose of irradiation was increased by 5{\%} increments from 30 grays equivalents (GyE) to 36.8 GyE. Surgery was to be performed 2 to 4 weeks after the completion of CIRT. Results: The study enrolled 26 patients. At the time of restaging after CIRT, disease progression with distant metastasis or refusal ruled out 5 patients from surgery. Twenty-one of 26 patients (81{\%}) patients underwent surgery. The pattern of initial disease progression was distant metastasis in 17 patients (65{\%}) and regional recurrence in 2 patients (8{\%}). No patients experienced local recurrence. The 5-year survival rates for all 26 patients and for those who underwent surgery were 42{\%} and 52{\%}, respectively. Conclusions: Preoperative, short-course CIRT followed by surgery is feasible and tolerable without unacceptable morbidity.",
author = "Makoto Shinoto and Shigeru Yamada and Shigeo Yasuda and Hiroshi Imada and Yoshiyuki Shioyama and Hiroshi Honda and Tadashi Kamada and Hirohiko Tsujii and Hiromitsu Saisho",
year = "2013",
month = "1",
day = "1",
doi = "10.1002/cncr.27723",
language = "English",
volume = "119",
pages = "45--51",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Phase 1 trial of preoperative, short-course carbon-ion radiotherapy for patients with resectable pancreatic cancer

AU - Shinoto, Makoto

AU - Yamada, Shigeru

AU - Yasuda, Shigeo

AU - Imada, Hiroshi

AU - Shioyama, Yoshiyuki

AU - Honda, Hiroshi

AU - Kamada, Tadashi

AU - Tsujii, Hirohiko

AU - Saisho, Hiromitsu

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: The authors evaluated the tolerance and efficacy of carbon-ion radiotherapy (CIRT) as a short-course, preoperative treatment and determined the recommended dose needed to reduce the risk of postoperative local recurrence without excess injury to normal tissue. Methods: Patients radiographically defined with potentially resectable pancreatic cancer were eligible. A preoperative, short-course, dose-escalation study was performed with fixed 8 fractions in 2 weeks. The dose of irradiation was increased by 5% increments from 30 grays equivalents (GyE) to 36.8 GyE. Surgery was to be performed 2 to 4 weeks after the completion of CIRT. Results: The study enrolled 26 patients. At the time of restaging after CIRT, disease progression with distant metastasis or refusal ruled out 5 patients from surgery. Twenty-one of 26 patients (81%) patients underwent surgery. The pattern of initial disease progression was distant metastasis in 17 patients (65%) and regional recurrence in 2 patients (8%). No patients experienced local recurrence. The 5-year survival rates for all 26 patients and for those who underwent surgery were 42% and 52%, respectively. Conclusions: Preoperative, short-course CIRT followed by surgery is feasible and tolerable without unacceptable morbidity.

AB - Background: The authors evaluated the tolerance and efficacy of carbon-ion radiotherapy (CIRT) as a short-course, preoperative treatment and determined the recommended dose needed to reduce the risk of postoperative local recurrence without excess injury to normal tissue. Methods: Patients radiographically defined with potentially resectable pancreatic cancer were eligible. A preoperative, short-course, dose-escalation study was performed with fixed 8 fractions in 2 weeks. The dose of irradiation was increased by 5% increments from 30 grays equivalents (GyE) to 36.8 GyE. Surgery was to be performed 2 to 4 weeks after the completion of CIRT. Results: The study enrolled 26 patients. At the time of restaging after CIRT, disease progression with distant metastasis or refusal ruled out 5 patients from surgery. Twenty-one of 26 patients (81%) patients underwent surgery. The pattern of initial disease progression was distant metastasis in 17 patients (65%) and regional recurrence in 2 patients (8%). No patients experienced local recurrence. The 5-year survival rates for all 26 patients and for those who underwent surgery were 42% and 52%, respectively. Conclusions: Preoperative, short-course CIRT followed by surgery is feasible and tolerable without unacceptable morbidity.

UR - http://www.scopus.com/inward/record.url?scp=84872760142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872760142&partnerID=8YFLogxK

U2 - 10.1002/cncr.27723

DO - 10.1002/cncr.27723

M3 - Article

C2 - 22744973

AN - SCOPUS:84872760142

VL - 119

SP - 45

EP - 51

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -